Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
Date
2022-09-01ICR Author
Author
Begum, P
Cui, W
Popat, S
Type
Journal Article
Metadata
Show full item recordAbstract
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
Collections
Subject
Case report
Lorlatinib
Non–small cell lung cancer
ROS1 fusion
ctDNA
Language
eng
Date accepted
2022-06-28
License start date
2022-09-01
Citation
JTO Clinical and Research Reports, 2022, 3 (9), pp. 100376 -
Publisher
ELSEVIER